WHAT CBD DOSE IS RIGHT FOR ME?

 

CANNABIDIOL (CBD), a non-psychoactive component of the marijuana plant, has generated significant interest among scientists and physicians in recent years – but how it exerts its therapeutic impact on a molecular level is still being sorted out. Cannabidiol (CBD) is one of at least 85 active cannabinoids identified in cannabis. It is a major phytocannabinoid, accounting for up to 40% of the plant's extract. CBD is considered to have a wider scope of potential medical applications than tetrahydrocannabinol (THC).

 

What CBD Dose is right for me?

 

Even though Cannabidiol is considered non-psychoactive, it is suggested that you use with the same degree of safety applied when dosing with THC.

 

WHAT TYPE OF USER AM I?

 

These are SUGGESTED amounts of CBD over a 24 hour period to help YOU establish your own level of tolerance. If you are unsure about where to start seek the advice of an expert BEFORE consumption to help in establishing your own safe level of cannabis consumption.

 

First Timer

 

Frequency of use: Never

 

CBD (activated) amount suggested over a 24 hour period:​ 2-5 MG

 

Occasional

 

Frequency of use: once a month

 

CBD (activated) amount suggested over a 24 hour period:​ 6-10 MG

 

Advanced

 

Frequency of use: once a week

 

CBD (activated) amount suggested over a 24 hour period:11-20 MG

 

Expert

 

Frequency of use: once a day

 

CBD (activated) amount suggested over a 24 hour period:​ 21+ 

 

Research

The bud of a Cannabis sativa flower coated with trichomes bearing cannabidiol and other cannabinoids

Neurological effects

Cannabidiol has been seen to be an anticonvulsant in animals, but controlled studies in humans are lacking.

Transdermal CBD is neuroprotective in animals.

Dravet syndrome

Dravet syndrome is a rare form of epilepsy that is difficult to treat. It is a catastrophic form of intractable epilepsy that begins in infancy. Initial seizures are most often prolonged events and in the second year of life other seizure types begin to emerge. A number of high profile and anecdotal reports have sparked interest in treatment of Dravet syndrome with CBD. GW Pharmaceuticals is seeking FDA approval to market a formulation of CBD, under the tradename Epidiolex, as a treatment for Dravet syndrome. Epidiolex was granted fast-track status and is in late stage trials following positive early results from the drug. Some cannabis extract preparations containing CBD are marketed as dietary supplements and claim efficacy against Dravet Syndrome. One such preparation is marketed under the tradename Charlotte's web.

Psychotropic effect

A 2014 Cochrane Review concluded that the evidence is insufficient to conclude that CBD has anti-psychotic effects. Others have concluded it may have antipsychotic effects and may counteract the potential psychotomimetic effects of THC on individuals with latent schizophrenia; some reports show it to be an alternative treatment for schizophrenia that is safe and well-tolerated. Studies have shown CBD may reduce schizophrenic symptoms due to its apparent ability to stabilize disrupted or disabled NMDAreceptor pathways in the brain, which are shared and sometimes contested by norepinephrine and GABA. Studies have shown cannabidiol decreases activity of the limbic system and decreases social isolation induced by THC in rats.

Chronic cannabidiol administration in rats was found to produce reactions suggesting anxiety, indicating that prolonged treatment with cannabidiol might lead to anxiety. Those results have been contested by Gururajan, and contradict Réus, whose experimentation cover the same duration.

CBD-enhanced cannabis

Selective breeding by growers in the USA dramatically lowered the CBD content of cannabis; their customers preferred varietals that were more mind-altering due to a higher THC, lower CBD content.To meet the demands of medical cannabis patients, growers are currently developing more CBD-rich strains.

Industrial hemp

Several industrial hemp varieties can be legally cultivated in western Europe. A variety such as "Fedora 17" has a cannabinoid profile consistently around 1% cannabidiol (CBD) with THC less than 0.1%.

Extraction can be done with olive oil, ethanol, or CO2, and other nonpolar to semipolar solvents.

Pharmacodynamics

Cannabidiol has a very low affinity for CB1 and CB2 receptors but acts as an indirect antagonist of their agonists. While one would assume that this would cause cannabidiol to reduce the effects of THC, it may potentiate THC's effects by increasing CB1 receptor density or through another CB1-related mechanism. It may also extend the duration of the effects of THC via inhibition of the cytochrome P-450-3A and 2C enzymes.

Recently, it was found to be an antagonist at the putative new cannabinoid receptor, GPR55, a GPCR expressed in the caudate nucleusand putamen. Cannabidiol has also been shown to act as a 5-HT1A receptor partial agonist,  an action which may be involved in its antidepressant, anxiolytic, and neuroprotective effects. Cannabidiol is an allosteric modulator of μ and δ-opioid receptors. Cannabidiol's pharmacological effects have also been attributed to PPAR-γ receptor agonism and intracellular calcium release.

Research suggests that CBD may exert some of its pharmacological action through its inhibition of FAAH, which may in turn increase the levels of endocannabinoids, such as anandamide, produced by the body.

Pharmacokinetic interactions

There is some preclinical evidence to suggest that cannabidiol may reduce THC clearance, modestly increasing THC's plasma concentrations resulting in a greater amount of THC available to receptors, increasing the effect of THC in a dose-dependent manner. Despite this the available evidence in humans suggests no significant effect of CBD on THC plasma levels.

 

CBD and FAAH:

 

Unlike psychoactive THC, CBD has little binding affinity to either the CB1 or CB2 cannabinoid receptors. Instead, CBD indirectly stimulates endogenous cannabinoid signaling by suppressing the enzyme fatty acid amide hydroxylase (“FAAH”) – the enzyme that breaks down anandamide.

Whereas the cannabinoid molecules found in cannabis are considered “exogenous ligands” to the cannabinoid (CB) receptor family, anandamide is an “endogenous” cannabinoid ligand – meaning it binds to one or more cannabinoid receptors and is found naturally inside the body. Anandamide favors the CB1 receptor, which in mammals is concentrated in the brain and central nervous system. Because FAAH is responsible for breaking down anandamide, less FAAH means more anandamide remains present in the body for a longer duration. More anandamide means greater CB1 activation.

By inhibiting the enzyme that metabolizes and destroys anandamide, CBD enhances the body’s innate protective endocannabinoid response. At the same time, CBD powerfully opposes the action of THC at the CB1 receptor, thereby muting the psychoactive effects of THC. CBD also stimulates the release of 2-AG, another endocannabinoid that activates both CB1 and CB2 receptors – CB2 receptors are predominant in the peripheral nervous system and the immune system.

 

The Vanilloid Receptor:

 

Whereas CBD does not bind to either of the two known cannabinoid receptors with particular affinity, it has been shown to directly interact with other, so-called “G-protein-coupled” receptors to confer its medicinal effect. CBD, for example, binds to the TRPV-1 receptor, which is known to mediate pain perception, inflammation and body temperature.

TRPV is the technical abbreviation for “transient receptor potential cation channel subfamily V.” Scientists also refer to it as the “vanilloid receptor,” named after the flavorful vanilla bean. Capsaicin — the pungent compound in hot chili peppers — is a well known activator of the TRVP-1 receptor. Vanilla contains eugenol, an essential oil that has antiseptic and analgesic properties, that also helps to unclog blood vessels. Historically, the vanilla bean has been used as a folk cure for headaches.

CBD is a TRPV-1 “agonist” or stimulant. This is likely one of the reasons why CBD-rich Cannabis may be a particularly effective treatment for neuropathic pain.

 

The Adenosine Receptor:

 

CBD may exert its anti-anxiety effect by activating adenosine receptors. Adenosine receptors play significant roles in cardiovascular function, regulating myocardial oxygen consumption and coronary blood flow. The adenosine (A2A) receptor has broad anti-inflammatory effects throughout the body.

Adenosine receptors also play a significant role in the brain. They down-regulate the release of other neurotransmitters such as dopamine and glutamate.

 

The Serotonin Receptor:

 

Jose Alexandre Crippa and his colleagues at the University of San Paulo in Brazil and at the King’s College in London have conducted pioneering research into CBD and the neural correlates of anxiety.

At high concentrations, CBD directly activates the 5-HT1A (hydroxytryptamine) serotonin receptor, thereby conferring an anti-depressant effect. This receptor is implicated in a range of biological and neurological processes, including, but not necessarily limited to, anxiety, addiction, appetite, sleep, pain perception, nausea and vomiting.

5-HT1A is a member of the family of 5-HT receptors, which are activated by the neurotransmitter serotonin. Found in both the central and peripheral nervous systems, 5-HT receptors trigger various intracellular cascades of chemical messages to produce either an excitatory or inhibitory response, depending on the chemical context of the message.

CBD triggers an inhibitory response that slows down 5-HT1A signaling. In comparison, LSD, mescaline, magic mushrooms, and several other hallucinogenic drugs activate a different type of 5-HT receptor that produces an excitatory response.

 

GPR55:

 

Whereas cannabidiol activates the TRPV-1 vanilloid receptor and 5-HT1A serotonin receptor, some studies indicate that CBD may also function as an antagonist that blocks, or deactivates, another G protein-coupled receptor known as GPR55.

GPR55 has been dubbed an “orphan receptor” because scientists are still not sure if it belongs to a larger family of receptors. Some researchers postulate that GPR55 may actually be a third cannabinoid receptor type.

GPR55 is widely expressed in the brain, especially in the cerebellum. It is involved in modulating blood pressure and bone density. GPR55 promotes osteoclast cell function, which facilitates bone reabsorption. Overactive GPR55 receptor signaling is associated with osteoporosis.

GPR55, when activated, also promotes cancer cell proliferation, according to 2010 study by researchers at the Chinese Academy of Sciences in Shanghai. This receptor is expressed in various types of cancer.

CBD is a GPR55 antagonist, as University of Aberdeen scientist Ruth Ross disclosed at the 2010 conference of the International Cannabinoid Research Society in Lund, Sweden.

By blocking GPR55 signaling, CBD might act to decrease both bone reabsorption and cancer cell proliferation. This is one of many molecular pathways through which CBD exerts an anti-cancer effect.

 

Combination Most Effective – CBD and THC Synergy:

 

Dr. Sean McAllister’s research at the Pacific Medical Center in San Francisco indicates that CBD reduces breast cancer cell proliferation, invasion and metastasis by inhibiting Id-1 gene expression. Best results were obtained when CBD was administered in combination with THC.

Several other studies underscore the therapeutic advantages for combining CBD and THC. CBD has been shown to be a potent anti-oxidant that mitigates the negative effects of oxygen free radicals. These highly reactive free radical chemicals are produced when animals use oxygen to burn food for fuel.

A great deal of data suggests that many problems associated with aging stem from the inability of an organism to protect itself against free-radical-induced inflammation and oxidative stress. This provides a fertile ground for the development of neurodegenerative and other age-related illnesses.

Cardiovascular, autoimmune, neurological disorders, cancers, and the aging process itself are all thought to have free radicals as a causative agent. Further, they are implicated in the formation of protein amyloid plaques — plaques that can attack neural synapses and prevent normal chemical and electrical signaling.

By binding up these free radicals, antioxidants can minimize the plaque formation cycle associated with the progression of Alzheimer’s disease. Accordingly, several studies have shown that CBD blocks Alzheimer’s plaque formation by a cannabinoid-receptor-independent mechanism.

The antioxidant properties of CBD exceed the antioxidant potency of either vitamin C or E. When combined with THC, the antioxidant properties of CBD grow even stronger. Once again, whole-plant Cannabis therapeutics has been shown to be far greater than the sum of the herb’s individual medicinal components.

 

 

 

The creator of this CBD content is Martin A Lee, director of Project CBD and the author of Smoke Signals: A Social History of Marijuana — Medical, Recreational and Social.

 

The information on this page is found verbatim at www.ProjectCBD.org and Wikipedia. Learn more about CBD and support their efforts by visting their site.

  • Twitter Square
  • Google+ Black Round
  • facebook-square

© 2014-19 

useCANNABISright, PLANTRICA